The Impact of New Antiretroic Therapeutic Schemes on the Cost for AIDS Treatment in Greece

Journal of Medical Systems

Volumn 25, Issue 1, 2001, Pages 73-80

  Kyriopoulos, John E ^a   Geitona, Mary A ^a   Paparizos, Vassilis A ^b   Kyriakis, Kyriakos K ^b   Botsi, Chrysoula A ^b   Stavrianeas, Nick G ^b  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b NONE

Author keywords

AIDS cost; Combination therapy; Cost effectiveness analysis; Greece; HIV disease

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; EVALUATION; FEE; GREECE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DRUG COSTS; GREECE; HEALTH CARE COSTS; HUMANS; PRESCRIPTION FEES;

EID: 0035259290     PISSN: 01485598     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005640500643     Document Type: Article

References (23)

1. Palella, J.R., Delaney, K.M., Moorman, A.C., et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338(13):853-60, 1998.
2. Michaels, S.H., Clark, R., and Kissinger, P., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 339(6):405-6, 1998.
3. Sepkowitz, K.A., Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 351(9098):228-30, 1998.
4. Mouton, Y., Alfandari, S., Valette, M., et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 11(12):F101-5, 1997.
5. Rose, D.N., AIDS drugs regimens that are worth their costs (editorial). JAMA 279(2):160-1, 1998.
6. De Luca, A., Antinori, A., and Ortona, L., Antiretroviral therapy and improving AIDS survival. JAMA 279(23):1874-5, 1998.
7. Beck, E., Tolley, K., Power, A., et al., The use and cost of HIV service provision in England in 1996. Pharmaco Economics 14:639-52, 1998.
8. Moore, R.D., and Bartlett, J.G., Combination antiretroviral therapy in HIV infection. PharmacoEconomics, 10:109-13, 1996.
9. Chancellor, J., Hill, A., Sabin, C., et al. Modeling the cost effectiveness of lamivudine/zidovudine combination therapy for HIV infection. Pharmaco Economics 12:1-13, 1997.
10. Anis, A., Hogg, R., Wand, X., et al., Modeling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. Pharmaco Economics 13:697-705, 1998.
11. Biddle, A., and Simpson, K., Modelling the cost-effectiveness of nevirapine triple combination therapy and dual combination therapy for the treatment of HIV disease in the United Kingdom. J. Drug Assessment 2:137-157, 1999.
12. Lawrence, J., Schapiro, J., Winters, M., et al., Salvage therapy with indinavir plus nevirapine in patients previously treated with two other protease inhibitors and multiple reverse transcriptase inhibitors. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, USA. February 1998 [abstract 422].
13. Staszewski, S., Hill, A., Bartlett, J., et al., Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: A meta-analysis of controlled trials. AIDS 11:477-83, 1997.
14. Ministry of Health and Welfare: Epidemiological Data for AIDS in Greece. Centre for Special Infectious Diseases, 31-12-1998 (in Greek).
15. Paparizos, V., Danaka, G., Kornarou, E., Kyriopoulos, J., Stavrianeas, N., and Baretzidis, A., The cost of AIDS according to the patient classification in Greece. Hellenic Rev. Dermatol. 7(2):92-99 (in Greek), 1996.
16. Kyriopoulos, J., Presentation and appraisal of the severity classification of AIDS patients for the implementation of a prospective financing system. In AIDS Economic: Cost Analysis, Management and Prospective Financing. (J. Kyriopoulos, H. Kornarou, M. Gitona, eds.), Exandas, Athens, 1996; pp. 13-24.
17. Kyriopoulos, J., Kornarou, H., Gitona, M., and Paparizos, V., Estimates of HIV/AIDS health care expenditure in Greece: An analytic approach for prospective financing. In The Economic and Social Impact of AIDS in Europe (D. Fitzsimmons, V. Hardy, and K. Tolley, eds.), Cassell, London, 1995, pp. 54-62.
18. Tolley, K., Postma, M., Jager, J., and Good, M., A standardized costing framework for HIV/AIDS hospital care in the European Union. In AIDS Cost Analysis and Patient Classification (J. Kyriopoulos, H. Kornarou, V. Paparizos, and M. Gitona, eds.), Exandas, Athans, 1998, pp. 37-51.
19. Rodriguez-Rosado, R. Jimenez-Nacher, I., Soriano, V., Anton, P., and Gonzalez-Lahoz, J, Virological failure and adherence to antiretroviral therapy in HIV - infected patients. AIDS 12(9):1112-3, 1998.
20. Birch, C., On the issue of cross-resistance between protease inhibitors. AIDS 12(6):680-1, 1998.
21. Hirsch, M.S., Conway, B., D'Aquila, R.T., Johnson, V.A., Brun-Vezinet, F., Clotet, B., et al., Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society-USA Panel. JAMA 279(24):1984-91, 1998.
22. Condra, J.H., Resisting resistance: maximising the durability of antiretroviral therapy. Ann. Intern. Med. 128(11):951-4, 1998.
23. Gitona, M., Papadimitriou, A., and Kyriopoulos, J., Economic evaluation of the preventive therapy for cerebral stroke disease under treatment with the combination of dipyridamole and aspirin. Neurology 8(3):150-157, 1999.